vs
Side-by-side financial comparison of Day One Biopharmaceuticals, Inc. (DAWN) and i3 Verticals, Inc. (IIIV). Click either name above to swap in a different company.
i3 Verticals, Inc. is the larger business by last-quarter revenue ($52.7M vs $39.8M, roughly 1.3× Day One Biopharmaceuticals, Inc.). i3 Verticals, Inc. runs the higher net margin — 0.9% vs -49.6%, a 50.5% gap on every dollar of revenue. On growth, i3 Verticals, Inc. posted the faster year-over-year revenue change (-14.6% vs -57.6%).
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.
The Prusa i3 is a family of fused filament fabrication 3D printers, manufactured by Czech company Prusa Research under the trademarked name Original Prusa i3. Part of the RepRap project, Prusa i3 printers were called the most used 3D printer in the world in 2016. The first Prusa i3 was designed by Josef Průša in 2012, and was released as a commercial kit product in 2015. The latest model is available in both kit and factory assembled versions. The Prusa i3's comparable low cost and ease of co...
DAWN vs IIIV — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $39.8M | $52.7M |
| Net Profit | $-19.7M | $484.0K |
| Gross Margin | — | — |
| Operating Margin | -60.9% | 3.1% |
| Net Margin | -49.6% | 0.9% |
| Revenue YoY | -57.6% | -14.6% |
| Net Profit YoY | -153.3% | -76.5% |
| EPS (diluted) | $-0.19 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $52.7M | ||
| Q3 25 | $39.8M | $46.0M | ||
| Q2 25 | $33.9M | $51.9M | ||
| Q1 25 | $30.8M | $63.1M | ||
| Q4 24 | — | $52.2M | ||
| Q3 24 | $93.8M | $32.0M | ||
| Q2 24 | — | $46.2M | ||
| Q1 24 | $0 | $58.0M |
| Q4 25 | — | $484.0K | ||
| Q3 25 | $-19.7M | $3.1M | ||
| Q2 25 | $-30.3M | $12.9M | ||
| Q1 25 | $-36.0M | $-154.0K | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $37.0M | $117.9M | ||
| Q2 24 | — | $-7.5M | ||
| Q1 24 | $-62.4M | $1.9M |
| Q4 25 | — | 3.1% | ||
| Q3 25 | -60.9% | 3.2% | ||
| Q2 25 | -103.1% | -9.3% | ||
| Q1 25 | -133.5% | 8.0% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | 31.6% | 10.6% | ||
| Q2 24 | — | -2.8% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | -49.6% | 6.7% | ||
| Q2 25 | -89.4% | 24.8% | ||
| Q1 25 | -117.0% | -0.2% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | 39.5% | 368.2% | ||
| Q2 24 | — | -16.3% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | $-0.19 | $0.14 | ||
| Q2 25 | $-0.29 | $0.50 | ||
| Q1 25 | $-0.35 | $0.00 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | $0.38 | $4.93 | ||
| Q2 24 | — | $-0.32 | ||
| Q1 24 | $-0.72 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $451.6M | $37.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $450.9M | $358.5M |
| Total Assets | $513.8M | $595.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $37.5M | ||
| Q3 25 | $451.6M | $66.7M | ||
| Q2 25 | $453.1M | $55.5M | ||
| Q1 25 | $473.0M | $7.7M | ||
| Q4 24 | — | $85.6M | ||
| Q3 24 | $558.4M | $86.5M | ||
| Q2 24 | — | $9.7M | ||
| Q1 24 | $317.9M | $3.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $12.0M | ||
| Q4 24 | — | $26.2M | ||
| Q3 24 | — | $26.2M | ||
| Q2 24 | — | $374.1M | ||
| Q1 24 | — | $369.6M |
| Q4 25 | — | $358.5M | ||
| Q3 25 | $450.9M | $389.6M | ||
| Q2 25 | $460.8M | $383.3M | ||
| Q1 25 | $479.5M | $385.2M | ||
| Q4 24 | — | $375.0M | ||
| Q3 24 | $555.5M | $379.7M | ||
| Q2 24 | — | $249.7M | ||
| Q1 24 | $296.8M | $249.3M |
| Q4 25 | — | $595.9M | ||
| Q3 25 | $513.8M | $638.4M | ||
| Q2 25 | $519.0M | $623.3M | ||
| Q1 25 | $534.4M | $646.4M | ||
| Q4 24 | — | $726.2M | ||
| Q3 24 | $600.8M | $730.7M | ||
| Q2 24 | — | $861.7M | ||
| Q1 24 | $326.6M | $625.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 1.50× | ||
| Q1 24 | — | 1.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $14.1M |
| Free Cash FlowOCF − Capex | — | $13.8M |
| FCF MarginFCF / Revenue | — | 26.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 29.18× |
| TTM Free Cash FlowTrailing 4 quarters | — | $6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.1M | ||
| Q3 25 | $-5.8M | $14.0M | ||
| Q2 25 | $-24.8M | $7.4M | ||
| Q1 25 | $-59.0M | $-27.1M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | $50.8M | $15.1M | ||
| Q2 24 | — | $8.1M | ||
| Q1 24 | $-49.7M | $10.7M |
| Q4 25 | — | $13.8M | ||
| Q3 25 | — | $13.5M | ||
| Q2 25 | $-24.8M | $6.8M | ||
| Q1 25 | $-59.3M | $-27.6M | ||
| Q4 24 | — | $11.0M | ||
| Q3 24 | $50.0M | $14.6M | ||
| Q2 24 | — | $7.2M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | — | 26.2% | ||
| Q3 25 | — | 29.5% | ||
| Q2 25 | -73.2% | 13.1% | ||
| Q1 25 | -192.8% | -43.8% | ||
| Q4 24 | — | 21.1% | ||
| Q3 24 | 53.4% | 45.6% | ||
| Q2 24 | — | 15.6% | ||
| Q1 24 | — | 17.1% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 1.0% | 0.8% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | 0.8% | 1.7% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | — | 29.18× | ||
| Q3 25 | — | 4.52× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.59× | ||
| Q3 24 | 1.37× | 0.13× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 5.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
IIIV
| License And Service | $35.7M | 68% |
| Proprietary Payments Revenue | $14.5M | 27% |
| Other Revenue | $2.5M | 5% |
